首页 News 正文

Lilly Pharmaceuticals and Kanezumab Injection Approved for Preventive Treatment of Adult Migraine in China

海角七号
300 0 0

On January 10th, Lilly Pharmaceuticals announced that Encore&Co; Reg; Jiakanezumab Injection has officially been approved by the National Medical Products Administration for the preventive treatment of adult migraines.
According to Eli Lilly Pharmaceuticals, Enjiale&Co; Reg; Jiakanezumab Injection is a humanized IgG4 type monoclonal antibody that can bind to calcitonin gene related peptide (CGRP) and block the binding of CGRP to its receptor, thereby achieving the therapeutic goal of preventing migraine. It is the first approved drug in China for the treatment of migraines by Eli Lilly Pharmaceuticals.
Jiakanezumab injection was approved for sale in the United States in September 2018 and has now been approved for sale in 60 countries and regions worldwide. (He Xinyi)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

海角七号 注册会员
  • 粉丝

    0

  • 关注

    1

  • 主题

    29